Steven Lo
Neurology · Washington, DCNPI 1154354074
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (40.6%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. Neurocrine Biosciences, Inc. accounts for 86.2% of it on its own, with 24 other manufacturers making up the rest. 2025 is the largest year on record at $32,154, more than ten times the $1,447 reported in 2019.
Across 429 payments — averaging $158.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$59K
- AbbVie$2K
- MDD US Operations, LLC$2K
- Teva Pharmaceuticals USA, Inc.$1K
- Medtronic$1K
- Merz Pharmaceuticals, LLC$553
- plus $3K from 19 others
Across 44 payments — averaging $5412.01 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Neurocrine Biosciences, Inc.$238K
What the payments were for
- Consulting fees$27,68041%
- Speaking & faculty fees$24,32136%
- Travel & lodging$5,7989%
- Food & beverage$9,95615%
- Education$3961%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 79 | $58,736 |
| AbbVie(2 entities) | 112 | $2,144 |
| MDD US Operations, LLC | 27 | $1,572 |
| Teva Pharmaceuticals USA, Inc. | 51 | $1,413 |
| Medtronic(2 entities) | 8 | $1,145 |
| Merz Pharmaceuticals, LLC | 17 | $553 |
| Acadia Pharmaceuticals Inc | 30 | $472 |
| Amneal Pharmaceuticals LLC | 19 | $378 |
| Kyowa Kirin, Inc. | 17 | $310 |
| GE HealthCare | 9 | $263 |
| Adamas Pharmaceuticals, Inc. | 12 | $229 |
| Abbott | 10 | $199 |
| Acorda Therapeutics, Inc | 8 | $168 |
| Sunovion Pharmaceuticals Inc. | 8 | $141 |
| Supernus Pharmaceuticals, Inc. | 1 | $65 |
| Lilly USA, LLC | 3 | $59 |
| Corium, LLC | 7 | $58 |
| Biogen | 2 | $48 |
| Otsuka America Pharmaceutical, Inc. | 2 | $44 |
| Avanir Pharmaceuticals, Inc. | 2 | $42 |
| Boehringer Ingelheim | 1 | $25 |
| Revance Therapeutics, Inc. | 1 | $25 |
| Azurity Pharmaceuticals, Inc. | 1 | $23 |
| Vertical Pharmaceuticals, LLC | 1 | $20 |
| Lundbeck LLC | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INGREZZA$56,844
- GOCOVRI$776
- AUSTEDO$131
- ACTIVA$119
- PERCEPT PC BRAINSENSE$104
How this compares
$68,151 in reported general payments places this provider in the 80th percentile of 113 neurology providers in District of Columbia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ApokynApomorphine Hcl | 13 | $389,512 |
| AustedoDeutetrabenazine | 23 | $279,385 |
| RytaryCarbidopa/Levodopa | 164 | $255,572 |
| NuplazidPimavanserin Tartrate | 28 | $223,048 |
| GocovriAmantadine Hcl | 39 | $128,670 |
| Austedo XrDeutetrabenazine | 21 | $111,025 |
| InbrijaLevodopa | 11 | $70,831 |
| Rasagiline Mesylate | 87 | $14,918 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 374 | $13,885 |
| OngentysOpicapone | 11 | $13,437 |
| Pramipexole ErPramipexole Di-Hcl | 30 | $12,816 |
| Galantamine ErGalantamine Hbr | 63 | $8,626 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 102 | $7,960 |
| Selegiline Hcl | 34 | $3,602 |
| Propranolol Hcl ErPropranolol Hcl | 24 | $2,710 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr | $1,413 | $390,41044 claims |
| Amneal Pharmaceuticals LLCRytary | $378 | $255,572164 claims |
| Acadia Pharmaceuticals IncNuplazid | $472 | $223,04828 claims |
| MDD US Operations, LLCGocovri | $1,572 | $128,67039 claims |
| Acorda Therapeutics, IncInbrija | $168 | $70,83111 claims |
| Neurocrine Biosciences, Inc.Ongentys | $58,736 | $13,43711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 113 neurology providers in District of Columbia.
Other neurology in Washington
- Laxman BahrooWashington$3.1M
- Fahd AmjadWashington$2M
- Jessica AilaniWashington$1.2M
- Yasar Torres-YaghiWashington$969K
- Benjamin OsborneWashington$747K
- Fernando PaganWashington$690K
- Faria AmjadWashington$557K
- Brian BarryWashington$359K
- Carrie DoughertyWashington$327K
- Carlo TornatoreWashington$318K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.